Biologically defined neuronal synuclein disease as a tool to advance drug development.
Saved in:
| Title: | Biologically defined neuronal synuclein disease as a tool to advance drug development. |
|---|---|
| Authors: | Pagano G; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland. gennaro.pagano@roche.com.; University of Exeter Medical School, London, UK. gennaro.pagano@roche.com., Dam T; Neumora Therapeutics, Watertown, MA, USA., Kerchner GA; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Galpern WR; Janssen Research & Development, LLC, Cambridge, MA, USA., Biagioni M; UCB Pharma, Brussels, Belgium., Karan R; Global Drug Development, Novartis Pharma AG, Basel, Switzerland., Jennings D; Denali Therapeutics Inc., South San Francisco, CA, USA., Peterschmitt MJ; Sanofi, Clinical Development Neurology, Cambridge, MA, USA., Nikolcheva T; Product Development Neurology, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Brundin P; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland. |
| Source: | NPJ Parkinson's disease [NPJ Parkinsons Dis] 2024 Dec 20; Vol. 10 (1), pp. 235. Date of Electronic Publication: 2024 Dec 20. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 101675390 Publication Model: Electronic Cited Medium: Print ISSN: 2373-8057 (Print) Linking ISSN: 23738057 NLM ISO Abbreviation: NPJ Parkinsons Dis Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39706882 AccessLevel: 2 PubType: Editorial & Opinion PubTypeId: editorialOpinion PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Biologically defined neuronal synuclein disease as a tool to advance drug development. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Pagano+G%22">Pagano G</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland. gennaro.pagano@roche.com.; University of Exeter Medical School, London, UK. gennaro.pagano@roche.com.<br /><searchLink fieldCode="AU" term="%22Dam+T%22">Dam T</searchLink>; Neumora Therapeutics, Watertown, MA, USA.<br /><searchLink fieldCode="AU" term="%22Kerchner+GA%22">Kerchner GA</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Galpern+WR%22">Galpern WR</searchLink>; Janssen Research & Development, LLC, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Biagioni+M%22">Biagioni M</searchLink>; UCB Pharma, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Karan+R%22">Karan R</searchLink>; Global Drug Development, Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Jennings+D%22">Jennings D</searchLink>; Denali Therapeutics Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Peterschmitt+MJ%22">Peterschmitt MJ</searchLink>; Sanofi, Clinical Development Neurology, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Nikolcheva+T%22">Nikolcheva T</searchLink>; Product Development Neurology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Brundin+P%22">Brundin P</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101675390%22">NPJ Parkinson's disease</searchLink> [NPJ Parkinsons Dis] 2024 Dec 20; Vol. 10 (1), pp. 235. <i>Date of Electronic Publication: </i>2024 Dec 20. – Name: TypePub Label: Publication Type Group: TypPub Data: Letter – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101675390 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2373-8057 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223738057%22">23738057 </searchLink><i>NLM ISO Abbreviation: </i>NPJ Parkinsons Dis <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39706882 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41531-024-00845-5 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 235 Titles: – TitleFull: Biologically defined neuronal synuclein disease as a tool to advance drug development. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Pagano G – PersonEntity: Name: NameFull: Dam T – PersonEntity: Name: NameFull: Kerchner GA – PersonEntity: Name: NameFull: Galpern WR – PersonEntity: Name: NameFull: Biagioni M – PersonEntity: Name: NameFull: Karan R – PersonEntity: Name: NameFull: Jennings D – PersonEntity: Name: NameFull: Peterschmitt MJ – PersonEntity: Name: NameFull: Nikolcheva T – PersonEntity: Name: NameFull: Brundin P IsPartOfRelationships: – BibEntity: Dates: – D: 20 M: 12 Text: 2024 Dec 20 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 2373-8057 Numbering: – Type: volume Value: 10 – Type: issue Value: 1 Titles: – TitleFull: NPJ Parkinson's disease Type: main |
| ResultId | 1 |
